

	Particulars [Refer notes below]	Standalone (Ind AS)				Consolidated (Ind AS)				Consolidated (IFRS)			
		Quarter ended 30/06/2016 (Unaudited)	Quarter ended 31/03/2016 (Unaudited)	Quarter ended 30/06/2015 (Unaudited)	Year ended 31/03/2016 (Unaudited)	Quarter ended 30/06/2016 (Unaudited)	Quarter ended 31/03/2016 (Unaudited)	Quarter ended 30/06/2015 (Unaudited)	Year ended 31/03/2016 (Unaudited)	Quarter ended 30/06/2016 (Unaudited)	Quarter ended 31/03/2016 (Unaudited)	Quarter ended 30/06/2015 (Unaudited)	Year ended 31/03/2016 (Audited)
1.	Income from operations												
	(a) Net sales / Income from operations (Net of excise duty)	15,810.23	16,940.76	12,259.03	58,173.88	18,832.07	21,740.23	16,258.32	73,683.39	18,832.07	21,740.23	16,258.32	73,683.39
	(b) Other operating income	598.45	2,116.78	219.11	2,961.10	598.45	1,072.28	219.11	1,916.60	598.45	1,072.28	219.11	1,916.60
	Total income from operations (net)	16,408.68	19,057.54	12,478.14	61,134.98	19,430.52	22,812.51	16,477.43	75,599.99	19,430.52	22,812.51	16,477.43	75,599.99
2.	Expenses												
	a. Cost of materials consumed	5,267.93	5,331.07	4,107.50	17,905.71	6,440.93	4,674.14	4,439.96	19,287.47	6,440.93	4,674.14	4,439.96	19,287.47
	b. Purchase of stock-in-trade	759.63	613.66	381.99	2,199.75	1,229.04	1,443.52	1,814.55	5,139.97	1,229.04	1,443.52	1,814.55	5,139.97
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(730.58)	374.52	(638.76)	(735.51)	(1,434.13)	1,321.58	(1,409.77)	(1,401.60)	(1,434.13)	1,321.58	(1,409.77)	(1,401.60)
	d. Employee benefits expense	1,791.31	2,300.22	1,479.49	7,662.54	3,719.87	3,481.64	2,862.59	13,781.95	3,719.87	3,488.85	2,860.17	13,781.95
	e. Depreciation and Amortisation expense	254.81	260.61	235.47	998.10	642.34	584.11	653.73	2,342.84	763.40	780.64	590.44	2,691.42
	f. Other expenses	3,311.33	5,295.99	2,858.24	16,492.23	5,684.13	8,867.73	5,176.72	24,463.23	5,684.13	8,867.82	5,176.72	24,464.48
	Total expenses	10,654.43	14,176.07	8,423.93	44,522.82	16,282.18	20,372.72	13,537.78	63,613.86	16,403.24	20,576.55	13,472.07	63,963.69
3.	Profit from operations before other Income, finance costs & exceptional items (1-2)	5,754.25	4,881.47	4,054.21	16,612.16	3,148.34	2,439.79	2,939.65	11,986.13	3,027.28	2,235.96	3,005.36	11,636.30
4.	Other income	979.30	669.17	260.39	1,172.83	759.21	116.93	53.71	200.00	759.21	116.93	53.71	200.00
5.	Profit from ordinary activities before finance costs and exceptional items (3+4)	6,733.55	5,550.64	4,314.60	17,784.99	3,907.55	2,556.72	2,993.36	12,186.13	3,786.49	2,352.89	3,059.07	11,836.30
6.	Finance costs	110.36	102.62	82.51	362.24	430.41	475.00	419.15	1,788.85	430.41	475.00	419.15	1,788.85
7.	Profit from ordinary activities after finance costs but before Exceptional Items (5-6)	6,623.19	5,448.02	4,232.09	17,422.75	3,477.14	2,081.72	2,574.21	10,397.28	3,356.08	1,877.89	2,639.92	10,047.45
8.	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
9.	Profit/(Loss) from ordinary activities before tax (7-8)	6,623.19	5,448.02	4,232.09	17,422.75	3,477.14	2,081.72	2,574.21	10,397.28	3,356.08	1,877.89	2,639.92	10,047.45
10.	Tax expense	1,435.14	326.28	846.36	2,561.79	1,209.33	594.33	745.07	2,969.24	1,174.94	448.16	730.53	3,028.40
11.	Net Profit/(Loss) from ordinary activities after tax (9-10)	5,188.05	5,121.74	3,385.73	14,860.96	2,267.81	1,487.39	1,829.14	7,428.04	2,181.14	1,429.73	1,909.39	7,019.05
12.	Extraordinary items (net of tax expense)	-	-	-	-	-	-	-	-	-	-	-	-
13.	Net Profit/(Loss) for the period (11-12)	5,188.05	5,121.74	3,385.73	14,860.96	2,267.81	1,487.39	1,829.14	7,428.04	2,181.14	1,429.73	1,909.39	7,019.05
14.	Share of profit/(loss) of associates	-	-	-	-	-	-	-	-	-	-	-	-
15.	Minority interest	-	-	-	-	0.01	(0.75)	(0.31)	(1.93)	0.01	(0.75)	(0.31)	(1.93)
16.	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13-14-15)	5,188.05	5,121.74	3,385.73	14,860.96	2,267.80	1,488.14	1,829.45	7,429.97	2,181.13	1,430.48	1,909.70	7,020.98
17.	Other comprehensive income (after tax)	(12.64)	(13.44)	(8.12)	(53.74)	206.71	(802.52)	(781.52)	(3,168.07)	314.44	(764.57)	(733.87)	(2,996.86)
18.	Total comprehensive income	5,175.41	5,108.30	3,377.61	14,807.22	2,474.51	685.62	1,047.93	4,261.90	2,495.57	665.91	1,175.83	4,024.12
19.	Paid-up Equity share capital (Face value per share Re. 1)	282.17	282.16	282.16	282.16	282.17	282.16	282.16	282.16	282.17	282.16	282.16	282.16
20.	Reserves excluding Revaluation reserves												42,420.30
21.i	Earning Per Share (before extraordinary items) (of Re 1/- each) (not annualised)												
	Basic Earnings Per Share (in Rupees)	18.39	18.15	12.29	52.94	8.04	5.28	6.66	26.47	7.73	5.07	6.91	25.01
	Diluted Earnings Per Share (in Rupees)	18.38	18.15	12.28	52.93	8.03	5.28	6.65	26.46	7.72	5.07	6.91	25.00
21.ii	Earning Per Share (after extraordinary items) (of Re 1/- each) (not annualised)												
	Basic Earnings Per Share (in Rupees)	18.39	18.15	12.29	52.94	8.04	5.28	6.66	26.47	7.73	5.07	6.91	25.01
	Diluted Earnings Per Share (in Rupees)	18.38	18.15	12.28	52.93	8.03	5.28	6.65	26.46	7.72	5.07	6.91	25.00

Notes:

- The above results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors held on 12 August, 2016
- The list of subsidiaries as of 30 June, 2016 is provided in Annexure A
- The Company operates in one reportable business segment i.e., Pharmaceuticals.
- During the quarter ended 30 June, 2016, pursuant to Employee Stock Option Scheme 2003, the Company converted 8,000 options into equity shares of Re.1 each. As at 30 June, 2016, 49,000 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- Tax expenses is computed after considering MAT credit and other income tax benefits.
- Diluted EPS has been computed considering the effect of conversion of ESOPs.
- The Company has for the first time adopted Indian Accounting Standards ("Ind AS") from 1 April, 2016 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34. The format for unaudited quarterly financial results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015 dated 30 November, 2015 has been modified to comply with the requirements of SEBI's circular dated 5 July, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 which are applicable to companies that are required to comply with Ind AS. The Company has also voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per IFRS in the format as per Regulation 33(1)(c) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

- Reconciliation between financial results as previously reported under previous GAAP (Indian GAAP) and Ind AS for the quarter ended 30 June, 2015.

Particulars	Amount in Rs. Million	
	Standalone	Consolidated
Net Profit under previous GAAP	3,352.02	1,782.66
Impact of Depreciation/amortisation	30.72	43.69
Impact of actuarial gain/(loss)	13.44	(2.40)
Impact of Deferred tax	(10.44)	5.50
Net Profit for the period under Ind AS	3,385.73	1,829.45

- During the quarter, the Company has issued U.S.\$170 Million 2% Resettable Onward Starting Equity-linked Securities due 2022. Post 30 June, 2016, the Company has issued the upside option of U.S.\$30 Million 2% Resettable Onward Starting Equity-linked Securities due 2022 and has also issued U.S.\$200 Million 4.5% Senior Notes due 2021.
- Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 the Statutory Auditors have carried out a limited review of the Standalone and Consolidated financial results for the quarter ended 30 June, 2016. The Ind AS and IFRS compliant corresponding figures in the previous period have not been subjected to limited review or Audit, unless specified. However, the management has exercised due diligence to ensure that such financial results provide a true and fair view of its affairs.
- Previous period's figures have been re-grouped/re-classified wherever necessary.

For and on behalf of the Board of Directors

Glenn Saldanha
Chairman & Managing Director

Mumbai, 12 August, 2016